{
    "clinical_study": {
        "@rank": "93917", 
        "acronym": "Enchant", 
        "arm_group": [
            {
                "arm_group_label": "HER2+ breast cancer", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Triple negative breast cancer", 
                "arm_group_type": "Experimental", 
                "description": "Closed to enrollment"
            }, 
            {
                "arm_group_label": "ER/PR+ Refractory to Prior Hormonal Treatment", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if ganetespib (STA-9090) is effective in the\n      treatment of patients with HER2+ or triple negative breast cancer who have not received\n      prior systemic treatment in the metastatic setting."
        }, 
        "brief_title": "An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "HER-2 Positive Breast Cancer", 
            "Triple Negative Breast Cancer", 
            "ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed diagnosis of invasive breast cancer.\n\n          -  Stage IV disease.\n\n          -  Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be\n             refractory to at least one prior hormonal treatment.\n\n          -  ECOG Performance status 0-1.\n\n          -  Measurable disease per RECIST (1.1).\n\n          -  Adequate hematological function per protocol.\n\n          -  Adequate hepatic function per protocol.\n\n          -  Adequate renal function per protocol.\n\n          -  Negative serum pregnancy test at study entry for patients of childbearing potential.\n\n          -  Ability to understand and sign written consent and to comply with the study protocol.\n\n        Exclusion Criteria:\n\n          -  Presence of active or untreated CNS metastases as determined by MRI/CT scan performed\n             during screening.\n\n          -  Active malignancies other than MBC within the last 5 years except adequately treated\n             in situ carcinoma of the cervix uteri or basal  or squamous cell carcinoma of the\n             skin.\n\n          -  Bone as the only site of metastatic disease from breast cancer.\n\n          -  Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a\n             limited area other than the sole site of measurable disease is allowed, if received\n             prior to initiation of ganetespib treatment. Patients must have completed treatment\n             and recovered from all acute treatment-related toxicities prior to administration of\n             first dose of ganetespib.\n\n          -  Pregnancy or lactation.\n\n          -  Known serious cardiac illness.\n\n          -  Uncontrolled intercurrent illness per protocol.\n\n          -  Other severe acute or chronic medical condition or abnormality that may increase the\n             risk associated with study participation or study drug administration, or may\n             interfere with the interpretation of study results, or that in the judgment of the\n             investigator would make the patient inappropriate for entry into the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677455", 
            "org_study_id": "9090-11"
        }, 
        "intervention": {
            "arm_group_label": [
                "HER2+ breast cancer", 
                "Triple negative breast cancer", 
                "ER/PR+ Refractory to Prior Hormonal Treatment"
            ], 
            "description": "Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.", 
            "intervention_name": "ganetespib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hsp90 inhibitor", 
            "ganetespib", 
            "STA 9090"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35249"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30341"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Argentina"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosario Santa Fe", 
                        "country": "Argentina", 
                        "zip": "S2000KZE"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "B-1000"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "01246"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Gangnam-GU"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Jongno-Gu"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Seodaemun-GU"
                    }, 
                    "name": "Synta Pharmacuetical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Songpa-Gu"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "zip": "EH4 2XU"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G12 0YN"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG51PB"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom", 
                        "zip": "OX3 9DU"
                    }, 
                    "name": "Synta Pharmaceuticals Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peterborough", 
                        "country": "United Kingdom", 
                        "zip": "PE3 9GZ"
                    }, 
                    "name": "Synta Pharmaceutical Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Belgium", 
                "Brazil", 
                "Korea, Republic of", 
                "Peru", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective response rate is based on RECIST criteria", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Progressive disease based on RECIST criteria.  CT scans at week 6, week 12 and every 6 weeks thereafter for the duration of the study.", 
            "measure": "Duration of response and progression free survival", 
            "safety_issue": "No", 
            "time_frame": "Every six weeks until progression"
        }, 
        "source": "Synta Pharmaceuticals Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Synta Pharmaceuticals Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}